뇌졸중 치료제 시장 : 점유율 분석, 업계 동향과 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the stroke therapeutics market size is estimated to reach USD 4.87 billion in 2026, and is projected to climb to USD 7.20 billion by 2031, at a CAGR of 8.13% during the forecast period (2026-2031).

This report is Segmented by Type (Ischemic Stroke and Hemorrhagic Stroke), Drug Class (Antithrombotic Agents, and More), Route of Administration (Oral, Intravenous, and More), Distribution Channel (Hospital, Retail, and Online Pharmacies), End-User (Hospitals, and More), and Geography (North America, Europe, Asia-Pacific, MEA, and South America). Market Forecasts are Provided in Value (USD).

Global Stroke Therapeutics Market Trends and Insights

Rising Prevalence of Stroke in the Aging Population

Worldwide, the share of people aged >=60 years will double between 2015 and 2050, and stroke risk doubles every decade after 55. In the United States alone, about 795,000 strokes occur yearly, 610,000 of them first-ever events. Co-morbid hypertension, atrial fibrillation, and diabetes magnify demand for preventive anticoagulants and antihypertensives. Japan's population already skews old, with 29% of the population aged 65 or older in 2024, resulting in high prescription volumes for secondary prevention medicines. The U.S. FDA's fast-track mechanisms are streamlining the development of geriatric-appropriate formulations that recognize the altered pharmacokinetics in older adults.

Increasing Investments in R&D and Advanced Therapies

Biopharmaceutical pipelines list more than 100 active stroke programs, backed by NIH's USD 218 million stroke research allocation in FY 2024. Focus areas range from NMDA antagonists to stem-cell implants, aiming to lengthen or bypass the narrow 4.5-hour thrombolytic window. PhRMA notes that stroke joins Alzheimer's and Parkinson's as top neuro priorities, driving capital into cell-based regeneration platforms. Late-stage attrition remains high; however, the commercial upside of a first-in-class neuroprotectant continues to drive strong investor appetite.

Patent Expiries Accelerating Generic Erosion

Clopidogrel and multiple direct oral anticoagulants are losing exclusivity, triggering price drops of over 80% within the first year of generics. While generics widen access, they compress revenue, prompting originators to adopt novel mechanisms and fixed-dose combinations. Apixaban's initial generic entries in 2024 exemplify the looming revenue cliff.

Other drivers and restraints analyzed in the detailed report include:

1. Favorable Reimbursement Policies for Thrombolytic Agents
2. Emergence of Gene-Based Neuroprotective Platforms
3. High Cost of Novel Biologics

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Ischemic stroke controlled 62.45% of the stroke therapeutics market in 2025, mirroring its 87% share of global stroke incidence. The stroke therapeutics market size for ischemic interventions is buoyed by widespread alteplase protocols and expanding thrombectomy eligibility. Tenecteplase adoption adds convenience, reducing nursing workload. Secondary prevention relies heavily on dual antiplatelet and direct oral anticoagulant regimens, anchoring recurring revenue.

Hemorrhagic stroke, though smaller, is projected to post a 10.35% CAGR, the fastest within the stroke therapeutics market. Novel reversal agents such as andexanet alfa address anticoagulant-related bleeds, while minimally invasive evacuation devices enhance outcomes. As Asian populations age and hypertension prevalence climbs, absolute hemorrhagic volumes support lucrative regional opportunities.

Antithrombotic agents represented 42.45% of the stroke therapeutics market size in 2025, driven by guideline-mandated lifelong prevention. Direct oral anticoagulants continue to outpace warfarin due to their fixed dosing and the elimination of routine monitoring. However, approaching patent cliffs bring generics that will redistribute value across the stroke therapeutics market.

Antihypertensives are on track for a 10.21% CAGR, reflecting tighter AHA target thresholds below 130/80 mmHg. Combination pills improve adherence and fuel premium pricing. For payers, sustained blood-pressure control offers proven stroke risk reduction, supporting favorable formulary placement.

Complete Report Scope:

• By Type
  • Ischemic Stroke
  • Hemorrhagic Stroke
• By Drug Class
  • Antithrombotic Agents
  • Neuroprotective Biologics
  • Antihypertensive Agents
  • Anti-Inflammatory & Antioxidants
• By Route of Administration
  • Oral
  • Intravenous
  • Intra-arterial
  • Subcutaneous / Intramuscular
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By End-User
  • Hospitals
  • Specialty Clinics
  • Ambulatory Surgical Centers
  • Other End-Users
• Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest Of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest Of Asia-Pacific
  • Middle East And Africa
    • GCC
    • South Africa
    • Rest Of Middle East And Africa
  • South America
    • Brazil
    • Argentina
    • Rest Of South America

Geography Analysis

North America accounted for 41.35% of the revenue in 2025. Regional stroke networks, CMS value-based purchasing, and broad insurance coverage facilitate the uptake of premium drugs. Canada follows similar universal-coverage pathways, albeit with province-specific formularies.

Europe contributes a consistent share, guided by EMA centralized approvals and national health systems that guarantee access to essential stroke drugs. The European Stroke Organisation harmonizes best practices, while individual countries fine-tune reimbursement according to cost-effectiveness dossiers.

The Asia-Pacific region is the fastest-growing, with a 9.54% CAGR. China's basic medical insurance now lists generic direct oral anticoagulants, widening access. India's National Programme for Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases, and Stroke funds regional hub-and-spoke stroke units, fostering demand for acute thrombolytics. Japan maintains high penetration of premium therapies thanks to ageing demographics and generous reimbursement.

1. Abbott Laboratories
2. Amgen
3. Athersys, Inc.
4. Bayer
5. Biogen
6. Boehringer Ingelheim
7. Bristol-Myers Squibb
8. CSL Behring
9. Daiichi Sankyo
10. Roche
11. Genentech
12. Johnson & Johnson
13. Merck
14. Pfizer
15. Portola Pharmaceuticals
16. ReNeuron Group
17. Sanofi
18. Takeda Pharmaceuticals

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rising Prevalence of Stroke in Aging Population
  • 4.2.2 Increasing Investments in R&D and Advanced Therapies
  • 4.2.3 Favorable Reimbursement Policies for Thrombolytic Agents
  • 4.2.4 Emergence of Gene-Based Neuroprotective Platforms
  • 4.2.5 AI-Enabled Hyper-Acute Stroke Triage Systems Boost Drug Utilization
  • 4.2.6 Expansion of Mobile Stroke Units in Emerging Markets
• 4.3 Market Restraints
  • 4.3.1 Patent Expiries Accelerating Generic Erosion
  • 4.3.2 High Cost of Novel Biologics
  • 4.3.3 Limited Cross-Border Cold Chain for Cell & Gene Therapies
  • 4.3.4 Physician Skepticism Toward Dual Antiplatelet De-Escalation Protocols
• 4.4 Value / Supply-Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces Analysis
  • 4.7.1 Threat of New Entrants
  • 4.7.2 Bargaining Power of Buyers/Consumers
  • 4.7.3 Bargaining Power of Suppliers
  • 4.7.4 Threat of Substitute Products
  • 4.7.5 Intensity of Competitive Rivalry

5 Market Size & Growth Forecasts (Value, USD)

• 5.1 By Type
  • 5.1.1 Ischemic Stroke
  • 5.1.2 Hemorrhagic Stroke
• 5.2 By Drug Class
  • 5.2.1 Antithrombotic Agents
  • 5.2.2 Neuroprotective Biologics
  • 5.2.3 Antihypertensive Agents
  • 5.2.4 Anti-Inflammatory & Antioxidants
• 5.3 By Route of Administration
  • 5.3.1 Oral
  • 5.3.2 Intravenous
  • 5.3.3 Intra-arterial
  • 5.3.4 Subcutaneous / Intramuscular
• 5.4 By Distribution Channel
  • 5.4.1 Hospital Pharmacies
  • 5.4.2 Retail Pharmacies
  • 5.4.3 Online Pharmacies
• 5.5 By End-User
  • 5.5.1 Hospitals
  • 5.5.2 Specialty Clinics
  • 5.5.3 Ambulatory Surgical Centers
  • 5.5.4 Other End-Users
• 5.6 Geography
  • 5.6.1 North America
    • 5.6.1.1 United States
    • 5.6.1.2 Canada
    • 5.6.1.3 Mexico
  • 5.6.2 Europe
    • 5.6.2.1 Germany
    • 5.6.2.2 United Kingdom
    • 5.6.2.3 France
    • 5.6.2.4 Italy
    • 5.6.2.5 Spain
    • 5.6.2.6 Rest Of Europe
  • 5.6.3 Asia-Pacific
    • 5.6.3.1 China
    • 5.6.3.2 Japan
    • 5.6.3.3 India
    • 5.6.3.4 South Korea
    • 5.6.3.5 Australia
    • 5.6.3.6 Rest Of Asia-Pacific
  • 5.6.4 Middle East And Africa
    • 5.6.4.1 GCC
    • 5.6.4.2 South Africa
    • 5.6.4.3 Rest Of Middle East And Africa
  • 5.6.5 South America
    • 5.6.5.1 Brazil
    • 5.6.5.2 Argentina
    • 5.6.5.3 Rest Of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (Includes Global Level Overview, Market Level Overview, Core Segments, Financials As Available, Strategic Information, Market Rank/Share For Key Companies, Products & Services, And Recent Developments)
  • 6.3.1 Abbott Laboratories
  • 6.3.2 Amgen Inc.
  • 6.3.3 Athersys, Inc.
  • 6.3.4 Bayer AG
  • 6.3.5 Biogen Inc.
  • 6.3.6 Boehringer Ingelheim International GmbH
  • 6.3.7 Bristol-Myers Squibb Company
  • 6.3.8 CSL Behring
  • 6.3.9 Daiichi Sankyo Company, Limited
  • 6.3.10 F. Hoffmann-La Roche Ltd.
  • 6.3.11 Genentech, Inc.
  • 6.3.12 Johnson & Johnson
  • 6.3.13 Merck & Co., Inc.
  • 6.3.14 Pfizer Inc.
  • 6.3.15 Portola Pharmaceuticals
  • 6.3.16 ReNeuron Group plc
  • 6.3.17 Sanofi S.A.
  • 6.3.18 Takeda Pharmaceutical Company Limited

7 Market Opportunities & Future Outlook

• 7.1 White-Space & Unmet-Need Assessment